After being approved by the U.S. Food and Drug Administration in June, Cubist Pharmaceuticals' new drug, Sivextro, is now available in the United States in daily I.V. and oral formulations for physician and hospital order.
Sivextro is approved for the treatment of acute bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus.
The oral treatment option of the drug has been available since June, according to Rob Perez, president and COO of Cubist, but the I.V. version is newly available. "We believe the features and utility of Sivextro offers physicians an effective option to treat acute bacterial skin and skin structure infections in a number of real-life patient settings — from the hospital to the home," he said in a news release.